NCT03700450View on ClinicalTrials.gov

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

November 22, 2022

Study Completion Date

December 1, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Cyclophosphamide

Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide

Trial Locations (3)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

69120

Universitätsklinikum Heidelberg, Heidelberg

Sponsors
All Listed Sponsors
collaborator

Esteve Pharmaceuticals GmbH

UNKNOWN

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER